DMD and Duchenne muscular dystrophy: Gene-addition, exon-skipping, stop codon readthrough, and genome-editing therapies can restore the expression of a partially functional dystrophin protein, whereas other therapeutic approaches aim to improve muscle function and quality by targeting pathways involved in DMD pathogenesis [6].